Delivery systems to increase the selectivity of antibiotics in phagocytic cells

Journal of Controlled Release

Volumn 125, Issue 3, 2008, Pages 210-227

  Briones, Elsa ^a   Isabel Colino, Clara ^a   Lanao, José M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antibiotics; Delivery systems; Intracellular infections; Phagocytic cells; Selectivity

Indexed keywords

ANTIBIOTICS; DISEASES; DRUG DELIVERY; PATIENT TREATMENT;

DELIVERY SYSTEMS; INTRACELLULAR INFECTIONS; PHAGOCYTIC CELLS;

CELLS;

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; BACITRACIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLOFAZIMINE; FLUCYTOSINE; LINCOSAMIDE; LIPOSOME; MACROLIDE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; POLYENE ANTIBIOTIC AGENT; POLYMYXIN; PYRIMETHAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFANILAMIDE; SURAMIN; TERBINAFINE; TETRACYCLINE; TRIMETHOPRIM; TRYPARSAMIDE; UNINDEXED DRUG; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ASPERGILLOSIS; BACTEREMIA; BRUCELLOSIS; CANDIDIASIS; CHAGAS DISEASE; CRYPTOCOCCOSIS; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SELECTIVITY; DRUG UPTAKE; ENDOCARDITIS; ERYTHROCYTE GHOST; GENITAL HERPES; HISTOPLASMOSIS; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEPROSY; LISTERIOSIS; MASTITIS; MENINGITIS; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PHAGOCYTE; PHAGOCYTOSIS; PHLEBITIS; PLAGUE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; ROCKY MOUNTAIN SPOTTED FEVER; SALMONELLOSIS; SEPTICEMIA; SHIGELLOSIS; SKIN LEISHMANIASIS; TARGET CELL; TOXOPLASMOSIS; TUBERCULOSIS; TYPHOID FEVER; TYPHUS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VISCERAL LEISHMANIASIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG DELIVERY SYSTEMS; MODELS, BIOLOGICAL; PHAGOCYTES; PHAGOCYTOSIS;

EID: 38349132566     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.10.027     Document Type: Review

References (210)

1. Ernst J.D., and Stendahl O. Phagocytosis of Bacteria and Bacterial Pathogenicity (2006), Cambridge University Press, Cambridge
2. Holmes B., Quie P.G., Windhorst D.B., Pollara B., and Good R.A. Protection of phagocytized bacteria from the killing action of antibiotics. Nature 210 41 (1966) 1131-1132
3. Carryn S., Chanteux H., Seral C., Mingeot-Leclercq M.P., Van Bambeke F., and Tulkens P.M. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North. Am. 17 3 (2003) 615-634
4. Mehta R.T. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob. Agents Chemother. 40 8 (1996) 1893-1902
5. Reinoso R.F., Lanao J.M., Lorente F., López F.G., and Domínguez-Gil A. Uptake of antibiotics by phagocytic cells: study methods and therapeutic implications. Rev. Esp. Quimioterap. 8 (1995) 100-108
6. Hazenbos W.L.W., and Brown E.J. Phagocytosis: receptors and biology. In: Ernst J.D., and Stendahl O. (Eds). Phagocytosis of Bacteria and Bacterial Pathogenicity (2006), Cambridge University Press, Cambridge 4-53
7. Ahsan F., Rivas I.P., Khan M.A., and Torres Suárez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 79 1-3 (2002) 29-40
8. Klempner M.S. White cells. In: Ristuccia A.M., and Cunha B.A. (Eds). Antimicrobial Therapy (1984), Raven Press, New York 513-517
9. Maurin M., and Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob. Agents Chemother. 45 11 (2001) 2977-2986
10. Gladue R.P., Bright G.M., Isaacson R.E., and Newborg M.F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 33 3 (1989) 277-282
11. Gladue R.P., and Snider M.E. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34 6 (1990) 1056-1060
12. Hand W.L. Interactions between antimicrobial agents, phagocytic cells and bacteria. Curr. Med. Chem. - Anti-Infec. Agents 2 1 (2003) 73-82 (10)
13. Prokesch R.C., and Hand W.L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 21 3 (1982) 373-380
14. Hand W.L., King-Thompson N., and Holman J.W. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 31 10 (1987) 1553-1557
15. Van Bambeke F., Barcia-Macay M., Lemaire S., and Tulkens P.M. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9 2 (2006) 218-230
16. Barcia-Macay M., Seral C., Mingeot-Leclercq M.P., Tulkens P.M., and Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50 3 (2006) 841-851
17. Carlier M.B., Scorneaux B., Zenebergh A., Desnottes J.F., and Tulkens P.M. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J. Antimicrob. Chemother. 26 B (1990) 27-39
18. Yamamoto T., Kusajima H., Hosaka M., Fukuda H., Oomori Y., and Shinoda H. Uptake and intracellular activity of AM-1155 in phagocytic cells. Antimicrob. Agents Chemother. 40 12 (1996) 2756-2759
19. Maurin M., and Raoult D. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J. Infect. Dis. 169 (1994) 330-336
20. Kutlin A., Roblin P.M., and Hammerschlag M.R. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob. Agents Chemother. 43 (1999) 2268-2272
21. Klempner M.S., and Styrt B. Clindamycin uptake by human neutrophils. J. Infect. Dis. 144 5 (1981) 472-475
22. Anderson R., Joone G., and van Rensburg C.E. An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus. J. Infect. Dis. 153 3 (1986) 593-600
23. Easmon C.S.F., and Crane J.P. Cellular uptake of clindamycin and lincomycin. Br. J. Exp. Pathol. 65 (1984) 725-730
24. Vosbeck K., James P.R., and Zimmermann W. Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob. Agents Chemother. 25 (1984) 735-741
25. Lutwyche P., Cordeiro C., Wiseman D.J., St-Louis M., Uh M., Hope M.J., Webb M.S., and Finlay B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 42 10 (1998) 2511-2520
26. Adams L.B., Sinha I., Franzblau S.G., Krahenbuhl J.L., and Mehta R.T. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob. Agents Chemother. 43 7 (1999) 1638-1643
27. Katragadda A., Bridgman R., and Betageri G. Effect of liposome composition and cholesterol on the cellular uptake of stavudine by human monocyte/macrophages. Cell. Mol. Biol. Lett. 5 (2000) 483-493
28. Sinha J., Mukhopadhyay S., Das N., and Basu M.K. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv. 7 4 (2000) 209-213
29. Schiffelers R., Storm G., and Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48 3 (2001) 333-344
30. Prior S., Gander B., Blarer N., Merkle H.P., Subira M.L., Irache J.M., and Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 15 2 (2002) 197-207
31. Roser M., Fischer D., and Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46 3 (1998) 255-263
32. Szoka Jr. F.C. The future of liposomal drug delivery. Biotechnol. Appl. Biochem. 12 5 (1990) 496-500
33. Grimaldi S., Lisi A., Pozzi D., and Santoro N. Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Res. Virol. 148 2 (1997) 177-180
34. Kansal R.G., Gómez-Flores R., Sinha I., and Mehta R.T. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Antimicrob. Agents Chemother. 41 1 (1997) 17-23
35. Whitehead T.C., Lovering A.M., Cropley I.M., Wade P., and Davidson R.N. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 17 11 (1998) 794-797
36. Torchilin V.P. Nanoparticulates as Drug Carriers (2006), Imperial College Press, London
37. Basu M.K., and Lala S. Nanoparticulate drug delivery to the reticuloendothelial system and to associated disorders. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 463-480
38. Schiffelers R.M., Storm G., and Bakker-Woudenberg I.A.J. Pharmaceutical nanocarriers in treatment and imaging of infection. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 697-711
39. Mukhopadhyay A., and Basu S.K. Intracellular delivery of drugs to macrophages. Adv. Biochem. Engin/Biotechnol. 84 (2003) 183-209
40. Vasir J.K., Reddy M.K., and Labhasetwar V.D. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci. 1 (2005) 47-64
41. Gref R., and Couvreur P. Nanocapsules: preparation, characterization and therapeutic applications. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 255-276
42. Agrawal A.K., and Gupta C.M. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliv. Rev. 41 2 (2000) 135-146
43. Kozubek A., Gubernator J., Przeworska E., and Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim. Pol. 47 3 (2000) 639-649
44. Perrett S., Golding M., and Williams W.P. A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J. Pharm. Pharmacol. 43 3 (1991) 154-161
45. Smistad G., Jacobsen J., and Sande S.A. Multivariate toxicity screening of liposomal formulations on a human buccal cell line. Int. J. Pharm. 330 1-2 (2007) 14-22
46. Berrocal M.C., Buján J., García-Honduvilla N., and Abeger A. Comparison of the effects of dimyristoyl and soya phosphatidylcholine liposomes on human fibroblasts. Drug Deliv. 7 (2000) 37-44
47. Mayhew E., Ito M., and Lazo R. Toxicity of non-drug-containing liposomes for cultured human cells. Exp. Cell. Res. 171 1 (1987) 195-202
48. Filion M.C., and Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta. 1329 2 (1997) 345-356
49. Adams D.H., Joyce G., Richardson V.J., Ryman B.E., and Wisniewski H.M. Liposome toxicity in the mouse central nervous system. J. Neurol. Sci. 31 2 (1977) 173-179
50. Yanez A.M., Wallace M., Ho R., Shen D., and Yaksh T.L. Touch-evoked agitation produced by spinally administered phospholipid emulsion and liposomes in rats. Structure-activity relation. Anesthesiology 82 5 (1995) 1189-1198
51. Karlowsky J.A., and Zhanel G.G. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin. Infect. Dis. 15 4 (1992) 654-667
52. Cordeiro C., Wiseman D.J., Lutwyche P., Uh M., Evans J.C., Finlay B.B., and Webb M.S. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model. Antimicrob. Agents Chemother. 44 3 (2000) 533-539
53. Gupta C.M., and Haq W. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Methods Enzymol. 391 (2005) 291-304
54. Vitas A.I., Díaz R., and Gamazo C. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrob. Agents Chemother. 40 1 (1996) 146-151
55. Bender A.R., von Briesen H., Kreuter J., Duncan I.B., and Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 6 (1996) 1467-1471
56. Löbenberg R., Araujo L., von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 1-3 (1998) 21-30
57. Von Briesen H., Ramge P., and Krueter J. Controlled release of antiretroviral drugs. AIDS Rev. 2 (2000) 31-38
58. Moghimi S.M., Vega E., García M.L., Al-Hanbali O.A.R., and Rutt K.J. Polymeric nanoparticles as drug carriers and controlled release implant devices. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 29-42
59. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21 23 (2000) 2475-2490
60. Pinto-Alphandary H., Andremont A., and Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13 3 (2000) 155-168
61. Prior S., Gamazo C., Irache J.M., Merkle H.P., and Gander B. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. Int. J. Pharm. 196 1 (2000) 115-125
62. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell. Mol. Life Sci. 60 1 (2003) 21-37
63. Müller R.H., Mader K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50 1 (2000) 161-177
64. Rawat M., Singh D., Saraf S., and Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 29 9 (2006) 1790-1798
65. Nel A., Xia T., Mädler L., and Li N. Toxic potential of materials at the nanolevel. Science 311 5761 (2006) 622-627
66. Smith A., and Hunneyball I.M. Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int. J. Pharm. 30 2-3 (1986) 215-220
67. Müller R.H., Maaben S., Weyhers H., Specht F., and Lucks J.S. Cytotoxicity of magnetide-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 138 (1996) 85-94
68. Freitas C., and Müller R.H. Spray-drying of solid lipid nanoparticles (SLN™). Eur. J. Pharm. Biopharm. 46 (1998) 145-151
69. Erni C., Suard C., Freitas S., Dreher D., Merkle H.P., and Walter E. Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials 23 23 (2002) 4667-4676
70. Lamprecht A., Bouligand Y., and Benoit J.P. New lipid nanocapsules exhibit sustained release properties for amiodarone. J. Control. Release 84 1-2 (2002) 59-68
71. Kayser O., Olbrich C., Croft S.L., and Kiderlen A.F. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol. Res. 90 2 (2003) S63-S70
72. Hoarau D., Delmas P., David S., Roux E., and Leroux J.C. Novel long-circulating lipid nanocapsules. Pharm. Res. 21 10 (2004) 1783-1789
73. Mäder K. Solid lipid nanoparticles as drug carriers. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 187-213
74. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 1 (2001) 3-19
75. Golenser J., Frankenburg S., Ehrenfreund T., and Domb A.J. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43 9 (1999) 2209-2214
76. Roseeuw E., Coessens V., Balazuc A.M., Lagranderie M., Chavarot P., Pessina A., Neri M.G., Schacht E., Marchal G., and Domurado D. Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin. Antimicrob. Agents Chemother. 47 11 (2003) 3435-3441
77. Nan A., Croft S.L., Yardley V., and Ghandehari H. Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis. J. Control. Release. 94 1 (2004) 115-127
78. Yang H., and Kao W.J. Dendrimers for pharmaceutical and biomedical applications. J. Biomater. Sci. Polym. Ed. 17 1-2 (2006) 3-19
79. Svenson S., and Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 57 15 (2005) 2106-2129
80. Dutta T., and Jain N.K. Targeting potencial and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770 (2007) 681-686
81. Kumar P.V., Asthana A., Dutta T., and Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 14 8 (2006) 546-556
82. Bhadra D., Bhadra S., and Jain N.K. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm. Res. 23 3 (2006) 623-633
83. Kuo J.H., Jan M.S., and Chiu H.W. Mechanism of cell death induced by cationic dendrimers in RAW 264.7 murine macrophage-like cells. J. Pharm. Pharmacol. 57 4 (2005) 489-495
84. Duncan R., and Izzo R.L. Dendrimer biocompatibility and toxicity. Adv. Drug. Deliv. Rev. 57 15 (2005) 2215-2237
85. Kader A., Davis P.J., Kara M., and Liu H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Control. Release. 55 2-3 (1998) 231-243
86. Liu S., Wang S., and Lu D.R. Lipoproteins as pharmaceutical carriers. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 173-186
87. Hu J., Liu H., and Wang L. Enhanced delivery of AZT to macrophages via acetylated LDL. J. Control. Release 69 3 (2000) 327-335
88. Mankertz J., Nundel M., von Baeyer H., and Riedel E. Low density lipoproteins as drug carriers in the therapy of macrophage-associated diseases. Biochem. Biophys. Res. Commun. 240 1 (1997) 112-115
89. Kader A., and Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release 80 1-3 (2002) 29-44
90. Hammel M., Laggner P., and Prassl R. Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem. Phys. Lipids. 123 2 (2003) 193-220
91. Lanao J.M., and Sayalero M.L. Cells and cell ghosts as drug carriers. In: Torchilin V.P. (Ed). Nanoparticulates as Drug Carriers (2006), Imperial College Press, London 329-348
92. Talwar N., and Jain N.K. Erythrocyte based delivery system of primaquine: in vitro characterization. J. Microencapsul. 9 3 (1992) 357-364
93. Chiarantini L., and Droleskey R.E. The use of resealed erythrocytes as carriers and bioreactors. In: Magnani M., and DeLoach J.R. (Eds). Advances in Experimental Medicine and Biology vol. 326 (1992) 269-277
94. Magnani M., Rossi L., Fraternale A., Bianchi M., Antonelli A., Crinelli R., and Chiarantini L. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 9 11 (2002) 749-751
95. Hamidi M., and Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 10 1 (2003) 9-20
96. Zocchi E., Tonetti M., Polvani C., Guida L., Benatti U., and De Flora A. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc. Natl. Acad. Sci. U.S.A. 86 6 (1989) 2040-2044
97. Gasparini A., Chiarantini L., and Kirch H. The use of resealed erythrocytes as carriers and bioreactors. In: Magnani M., and DeLoach J.R. (Eds). Advances in Experimental Medicine and Biology vol. 326 (1992) 291-297
98. Eichler H.G., Gasic S., Bauer K., Korn A., and Bacher S. In vivo clearance of antibody-sensitized human drug carrier erythrocytes. Clin. Pharmacol. Ther. 40 3 (1986) 300-303
99. Noel-Hocquet S., Jabbouri S., Lazar S., Maunier J.C., Guillaumet G., and Ropars C. Erythrocytes as carriers of new anti-opioid prodrugs: in vitro studies. Adv. Exp. Med. Biol. 326 (1992) 215-221
100. Bax B.E., Bain M.D., Talbot P.J., Parker-Williams E.J., and Chalmers R.A. Survival of human carrier erythrocytes in vivo. Clin. Sci. 96 2 (1999) 171-178
101. Lynch W.E., Sartiano G.P., and Ghaffar A. Erythrocytes as carriers of chemotherapeutic agents for targeting the reticuloendothelial system. Am. J. Hematol. 9 3 (1980) 249-259
102. Millán C.G., Marinero M.L., Castañeda A.Z., and Lanao J.M. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release 95 1 (2004) 27-49
103. Jain S., and Jain N.K. Engineered erythrocytes as a drug delivery system. Indian J. Pharm. Sci. 59 (1997) 275-281
104. Moss H.A., Tebbs S.E., Faroqui M.H., Herbst T., Isaac J.L., Brown J., and Elliott T.S. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur. J. Anaesthesiol. 17 11 (2000) 680-687
105. Valbonesi M., Bruni R., Florio G., Zanella A., and Bunkens H. Cellular contamination of plasma collected with various apheresis systems. Transfus. Apheresis Sci. 24 1 (2001) 91-94
106. Sugai Y., Sugai K., and Fuse A. Current status of bacterial contamination of autologous blood for transfusion. Transfus. Apheresis Sci. 24 3 (2001) 255-259
107. Álvarez F.E., Rogge K.J., Tarrand J., and Lichtiger B. Bacterial contamination of cellular blood components. A retrospective review at a large cancer center. Ann. Clin. Lab. Sci. 25 (1995) 283-290
108. Garcia I., Pascual A., Ballesta S., del Castillo C., and Perea E.J. Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 52 1 (2003) 24-28
109. Hand W.L., and Hand D.L. Interactions of dirithromycin with human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 37 12 (1993) 2557-2562
110. Hand W.L., and Hand D.L. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents 18 5 (2001) 419-425
111. Gardai S.J., Bratton D.L., Ogden C.A., and Henson P.M. Recognition ligands on apoptotic cells: a perspective. J. Leukoc. Biol. 79 5 (2006) 896-903
112. Van Lent P.L., Licht R., Dijkman H., Holthuysen A.E., Berden J.H., and van den Berg W.B. Uptake of apoptotic leukocytes by synovial lining macrophages inhibits immune complex-mediated arthritis. J. Leukoc. Biol. 70 5 (2001) 708-714
113. Paukner S., Kohl G., Jalava K., and Lubitz W. Sealed bacterial ghosts-novel targeting vehicles for advanced drug delivery of water-soluble substances. J. Drug Target. 11 3 (2003) 151-161
114. Huter V., Szostak M.P., Gampfer J., Prethaler S., Wanner G., Gabor F., and Lubitz W. Bacterial ghosts as drug carrier and targeting vehicles. J. Control. Release 61 1-2 (1999) 51-63
115. Klemens S.P., Cynamon M.H., Swenson C.E., and Ginsberg R.S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 34 6 (1990) 967-970
116. Fierer J., Hatlen L., Lin J.P., Estrella D., Mihalko P., and Yau-Young A. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob. Agents Chemother. 34 2 (1990) 343-348
117. Leitzke S., Bucke W., Borner K., Muller R., Hahn H., and Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob. Agents Chemother. 42 2 (1998) 459-461
118. Oh Y.K., Nix D.E., and Straubinger R.M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob. Agents Chemother. 39 9 (1995) 2104-2111
119. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr. Pharm. Des. 8 6 (2002) 475-482
120. Webb M.S., Boman N.L., Wiseman D.J., Saxon D., Sutton K., Wong K.F., Logan P., and Hope M.J. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob. Agents Chemother. 42 1 (1998) 45-52
121. Onyeji C.O., Nightingale C.H., Nicolau D.P., and Quintiliani R. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. Antimicrob. Agents Chemother. 38 3 (1994) 523-527
122. Duzgunes N., Flasher D., Reddy M.V., Luna-Herrera J., and Gangadharam P.R. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 40 11 (1996) 2618-2621
123. Vyas S.P., Kannan M.E., Jain S., Mishra V., and Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269 1 (2004) 37-49
124. Deol P., Khuller G.K., and Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41 6 (1997) 1211-1214
125. Gómez-Flores R., Hsia R., Tamez-Guerra R., and Mehta R.T. Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation. Antimicrob. Agents Chemother. 40 11 (1996) 2545-2549
126. Salem I.I., and Düzgünes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int. J. Pharm. 250 2 (2003) 403-414
127. Bakker-Woudenberg I.A., Lokerse A.F., and Roerdink F.H. Effect of lipid composition on activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes. Antimicrob. Agents Chemother. 32 10 (1988) 1560-1564
128. Agrawal A.K., Agrawal A., Pal A., Guru P.Y., and Gupta C.M. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug Target. 10 1 (2002) 41-45
129. Owais M., Ahmed I., Krishnakumar B., Jain R.K., Bachhawat B.K., and Gupta C.M. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Letters. 326 (1993) 56-58
130. Tremblay C., Barza M., Fiore C., and Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 26 2 (1984) 170-173
131. Gondal J.A., Swartz R.P., and Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33 9 (1989) 1544-1548
132. Graybill J.R., Craven P.C., Taylor R.L., Williams D.M., and Magee W.E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145 5 (1982) 748-752
133. Taylor R.L., Williams D.M., Craven P.C., Graybill J.R., Drutz D.J., and Magee W.E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am. Rev. Respir. Dis. 125 5 (1982) 610-611
134. Khan M.A., Nasti T.H., and Owais M. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J. Antimicrob. Chemother. 56 4 (2005) 726-731
135. Chakraborty K.K., and Naik S.R. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin-beta complexed with different chemically modified beta-ciclodextrins. J. Pharm. Pharm. Sci. 6 2 (2003) 231-237
136. van Etten E.W., van Vianen W., Hak J., and Bakker-Woudenberg I.A. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages. Antimicrob. Agents Chemother. 42 9 (1998) 2437-2439
137. Vyas S.P., Katare Y.K., Mishra V., and Sihorkar V. Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int. J. Pharm. 210 1-2 (2000) 1-14
138. Paul M., Durand R., Fessi H., Rivollet D., Houin R., Astier A., and Deniau M. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41 8 (1997) 1731-1734
139. Mehta R.T., Hopfer R.L., Gunner L.A., Juliano R.L., and Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31 12 (1987) 1897-1900
140. Mehta R.T., Hopfer R.L., McQueen T., Juliano R.L., and Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31 12 (1987) 1901-1903
141. Johnson E.M., Ojwang J.O., Szekely A., Wallace T.L., and Warnock D.W. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. 42 6 (1998) 1412-1416
142. Oakley K.L., Moore C.B., and Denning D.W. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob. Agents Chemother. 43 5 (1999) 1264-1266
143. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., Piscitelli S.C., and Walsh T.J. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182 1 (2000) 274-282
144. Wallace T.L., Paetznick V., Cossum P.A., Lopez-Berestein G., Rex J.H., and Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 41 10 (1997) 2238-2243
145. Nasti T.H., Khan M.A., and Owais M. Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model. J. Antimicrob. Chemother. 57 2 (2006) 349-352
146. Alonso-Vargas R., González-Álvarez L., Ruesga M.T., Carrillo-Muñoz A.J., Martín-Mazuelos E., Wallace T.L., Cossum P.A., Pontón J., and Quindos G. In vitro activity of a liposomal nystatin formulation (Nyotran) against Cryptococcus neoformans. Rev. Iberoam. Micol. 17 3 (2000) 90-92
147. Khan M.A., Jabeen R., Nasti T.H., and Mohammad O. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J. Antimicrob. Chemother. 55 2 (2005) 223-228
148. Mullen A.B., Baillie A.J., and Carter K.C. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42 10 (1998) 2722-2725
149. Tempone A.G., Perez D., Rath S., Vilarinho A.L., Mortara R.A., and de Andrade Jr. H.F. Targeting Leishmania chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J. Antimicrob. Chemother. 54 1 (2004) 60-68
150. Banerjee G., Nandi G., Mahato S.B., Pakrashi A., and Basu M.K. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J. Antimicrob. Chemother. 38 1 (1996) 145-150
151. Medda S., Mukhopadhyay S., and Basu M.K. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J. Antimicrob. Chemother. 44 6 (1999) 791-794
152. Banerjee G., Medda S., and Basu M.K. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrob. Agents Chemother. 42 2 (1998) 348-351
153. Oussoren C., Magnani M., Fraternale A., Casabianca A., Chiarantini L., Ingebrigsten R., Underberg W.J., and Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate. Int. J. Pharm. 180 2 (1999) 261-270
154. Mukherjee S., Das L., Kole L., Karmakar S., Datta N., and Das K.P. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J. Infect. Dis. 189 (2004) 1024-1034
155. Lecaroz C., Gamazo C., and Blanco-Prieto M.J. Nanocarriers with gentamicin to treat intracellular pathogens. J. Nanosci. Nanotechnol. 6 9-10 (2006) 3296-3302
156. Lecaroz C., Blanco-Prieto M.J., Burrell M.A., and Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J. Antimicrob. Chemother. 58 3 (2006) 549-556
157. Balland O., Pinto-Alphandary H., Viron A., Puvion E., Andremont A., and Couvreur P. Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles. J. Antimicrob. Chemother. 37 1 (1996) 105-115
158. Barrow E.L., Winchester G.A., Staas J.K., Quenelle D.C., and Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42 10 (1998) 2682-2689
159. O'Hara P., and Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 17 8 (2000) 955-961
160. Suárez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., and Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18 9 (2001) 1315-1319
161. Echevarria I., Barturen C., Renedo M.J., Troconiz I.F., and Dios-Vieitez M.C. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrob. Agents Chemother. 44 4 (2000) 898-904
162. Espuelas M.S., Legrand P., Campanero M.A., Appel M., Cheron M., Gamazo C., Barratt G., and Irache J.M. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J. Antimicrob. Chemother. 52 3 (2003) 419-427
163. Fukui H., Koike T., Saheki A., Sonoke S., and Seki J. A novel delivery system for amphotericin B with lipid nano-sphere (LNS). Int. J. Pharm. 265 1-2 (2003) 37-45
164. Fukui H., Koike T., Nakagawa T., Saheki A., Sonoke S., Tomii Y., and Seki J. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. Int. J. Pharm. 267 1-2 (2003) 101-112
165. Löbenberg R., Araujo L., and Krueter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44 (1997) 127-132
166. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. Int. J. Pharm. 196 2 (2000) 253-256
167. Falk R., Domb A.J., and Polacheck I.A. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43 8 (1999) 1975-1981
168. Mankertz J., Matthes E., Rokos K., von Baeyer H., Pauli G., and Riedel E. Selective endocytosis of fluorothymidine and azidothymidine coupled to LDL into HIV infected mononuclear cells. Biochim. Biophys. Acta. 1317 3 (1996) 233-237
169. Perno C.F., Santoro N., Balestra E., Aquaro S., Cenci A., Lazzarino G., Di Pierro D., Tavazzi B., Balzarini J., Garaci E., Grimaldi S., and Calio R. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus. Antiviral Res. 33 3 (1997) 153-164
170. Rossi L., Serafini S., Cappellacci L., Balestra E., Brandi G., Schiavano G.F., Franchetti P., Grifantini M., Perno C.F., and Magnani M. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. J. Antimicrob. Chemother. 47 6 (2001) 819-827
171. Franchetti P., Abu Sheikha G., Cappellacci L., Marchetti S., Grifantini M., Balestra E., Perno C., Benatti U., Brandi G., Rossi L., and Magnani M. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. Antiviral Res. 47 3 (2000) 149-158
172. Magnani M., Rossi L., Brandi G., Schiavano G.F., Montroni M., and Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A. 89 14 (1992) 6477-6481
173. Magnani M., Rossi L., Fraternale A., Silvotti L., Quintavalla F., Piedimonte G., Matteucci D., Baldinotti F., and Bendinelli M. FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5′-triphosphate. Vet. Immunol. Immunopathol. 46 1-2 (1995) 151-158
174. Benatti U., Giovine M., Damonte G., Gasparini A., Scarfi S., De Flora A., Fraternale A., Rossi L., and Magnani M. Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Biochem. Biophys. Res. Commun. 220 1 (1996) 20-25
175. Mehta R.T., Keyhani A., McQueen T.J., Rosenbaum B., Rolston K.V., and Tarrand J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 37 12 (1993) 2584-2587
176. Bermudez L.E. Use of liposome preparation to treat mycobacterial infections. Immunobiology 191 4-5 (1994) 578-583
177. Salem I.I., Flasher D.L., and Duzgunes N. Liposome-encapsulated antibiotics. Methods Enzymol. 391 (2005) 261-291
178. Khuller G.K., Kapur M., and Sharma S. Liposome technology for drug delivery against mycobacterial infections. Curr. Pharm. Des. 10 26 (2004) 3263-3274
179. Ahren I.L., Karlsson E., Forsgren A., and Riesbeck K. Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable Haemophilus influenzae. J. Antimicrob. Chemother. 50 6 (2002) 903-906
180. Pandey R., and Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55 4 (2005) 430-435
181. Jahn B., Rampp A., Dick C., Jahn A., Palmer M., and Bhakdi S. Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob. Agents Chemother. 42 10 (1998) 2569-2575
182. Eldem T., Arican-Cellat N., Agabeyoglu I., Akova M., and Kansu E. Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. Int. J. Pharm. 213 1-2 (2001) 153-161
183. Agatha W.K., and Wasan K.M. Development of liposomal polyene antibiotics: an historical perspective. J. Pharm. Pharmaceut. Sci. 6 1 (2003) 67-83
184. Maesaki S. Drug delivery system of anti-fungal and parasitic agents. Curr. Pharm. Des. 8 6 (2002) 433-440
185. Tomii Y. Lipid formulation as a drug carrier for drug delivery. Curr. Pharm. Des. 8 6 (2002) 467-474
186. Gibbs W.J., Drew R.H., and Perfect J.R. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev. Anti Infect. Ther. 3 2 (2005) 167-181
187. van Etten E.W., Stearne-Cullen L.E., ten Kate M., and Bakker-Woudenberg I.A. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob. Agents Chemother. 44 3 (2000) 540-545
188. Hillery A.M. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 24 (1997) 345-363
189. Kshirsagar N.A., Pandya S.K., Kirodian G.B., and Sanath S. Liposomal drug delivery system from laboratory to clinic. J. Postgrad. Med. 51 1 (2005) S5-S15
190. van Etten E.W., Chander H.R., Snijders S.V., and Bakker-Woudenberg I.A. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. J. Antimicrob. Chemother. 36 6 (1995) 961-974
191. Adler-Moore J., and Proffitt R.T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49 1 (2002) 21-30
192. Clemons K.V., and Stevens D.A. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42 4 (1998) 899-902
193. Carter K.C., Mullen A.B., Sundar S., and Kenney R.T. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 45 12 (2001) 3555-3559
194. Yardley V., and Croft S.L. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41 4 (1997) 752-756
195. Yardley V., and Croft S.L. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents. 13 4 (2000) 243-248
196. Gangneux J.P., Sulahian A., Garin Y.J., Farinotti R., and Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40 5 (1996) 1214-1218
197. Mullen A.B., Carter K.C., and Baillie A.J. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41 10 (1997) 2089-2092
198. Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R.N., Figueras C., Gradoni L., Kafetzis D.A., Ritmeijer K., Rosenthal E., Royce C., Russo R., Sundar S., and Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43 7 (2006) 917-924
199. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann. Trop. Med. Parasitol. 97 1 (2003) 135-142
200. Minodier P., Retornaz K., Horelt A., and Garnier J.M. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam. Clin. Pharmacol. 17 2 (2003) 183-188
201. Coukell A.J., and Brogden R.N. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55 4 (1998) 585-612
202. Torre-Cisneros J., Villanueva J.L., Kindelan J.M., Jurado R., and Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 17 4 (1993) 625-627
203. Barratt G., and Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr. Opin. Infect. Dis. 18 6 (2005) 527-530
204. Fraternale A., Casabianca A., Orlandi C., Cerasi A., Chiarantini L., Brandi G., and Magnani M. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. Antiviral Res. 56 3 (2002) 263-272
205. Schafer V., von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 4 (1992) 541-546
206. Lanao J.M., Briones E., and Colino C.I. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target. 15 1 (2007) 21-36
207. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog. Lipid. Res. 41 1 (2002) 27-65
208. Fridkin M., Tsubery H., Tzehoval E., Vonsover A., Biondi L., Filira F., and Rocchi R. Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. J. Pept. Sci.; 11 1 (2005) 37-44
209. Fraternale A., Casabianca A., Tonelli A., Chiarantini L., Brandi G., and Magnani M. New drug combinations for the treatment of murine AIDS and macrophage protection. Eur. J. Clin. Invest. 31 3 (2001) 248-252
210. Fraternale A., Casabianca A., Rossi L., Chiarantini L., Schiavano G.F., Palamara A.T., Garaci E., and Magnani M. Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. J. Antimicrob. Chemother. 52 4 (2003) 551-554